Status:
COMPLETED
An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Brief Summary
This observational, multi-center, open-label, prospective study will evaluate the relationship between serum interleukin-6 (IL-6) and C-reactive protein (CRP) levels and methoxy polyethylene glycol-ep...
Eligibility Criteria
Inclusion
- CKD participants undergoing dialysis
- Participants initiating ESA treatment with methoxy polyethylene glycol-epoetin beta or participants on stable methoxy polyethylene glycol-epoetin beta maintenance therapy
- Adequate iron status defined as: serum ferritin above or equal to 100 micrograms per liter (mcg/L) or transferrin saturation above or equal to 20 percent (%)
Exclusion
- Conditions known to cause inadequate response to ESA treatment
- Anemia other than symptomatic anemia associated with CKD
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT02238080
Start Date
December 1 2009
End Date
June 1 2012
Last Update
May 15 2017
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Haemek Hospital; Nephrology
Afula, Israel, 18101
2
Barzilai Medical Centre ; Nephrology and Hypertension
Ashkelon, Israel, 78306
3
Soroka Medical Center; Nephrology
Beersheba, Israel, 84101
4
Bnai Zion MC; Nephrology
Haifa, Israel, 31048